

Committee Name: Patient and Community Advisory Committee (PCAC)

David McMullen — Conflict of Interest Disclosure (May 2021)

David has received travel funding or payment to participate in numerous activities associated with Myeloma Canada from 2012 to 2020 and will be involved in future advocacy activities for drug or treatment access. David will possibly participate as a patient representative associated with treatments that may, in future, be evaluated by CADTH. He has also received travel funding or payment from the Canadian Cancer Trials Group from 2015 to 2019 to provide advice and comments as a patient representative on specific clinical trials and research work, and he continues to participate in research activities as a patient representative associated with treatments that may, in future, be evaluated by CADTH.

David received an honorarium from the International Myeloma Foundation for participating in a patient focus group. The honorarium was then donated back to the Foundation.

David has modest stock holdings in 2 pharmaceutical companies as part of a diversified retirement investment portfolio: Johnson & Johnson and Pfizer Inc.